Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Springer Science+Business Media New York 2015. Gene therapy is ideally suited to the treatment of inherited retinal degenerations in order to prevent blindness. The target area of the outer retina is small and relatively immune privileged, which facilitates the delivery of small volumes of vector without generating signifi cant immune reactions. Moreover, most of the currently untreatable forms of blindness have a genetic component, either monogenic such as in retinitis pigmentosa or as a result of several genes interacting along a common pathway, such as age-related macular degeneration, the commonest cause of legal blindness in the developed world. The self-contained nature of the eye also facilitates the application of gene therapy for sustained expression of intraocular proteins, such as inhibitors of angiogenesis or growth factors that might confer neuroprotection to dying cells. In this chapter, we review the indications and applications of gene therapy, concentrating specifi cally on adeno-associated viral (AAV) vectors, describing the protocols for production and administration of AAV vectors to the eye in the laboratory setting.

Original publication




Journal article



Publication Date





203 - 228